Bob Carter, MD, PhDChief, Neurosurgery Service at MGH
About Dr. Carter
Bob S. Carter, MD, PhD, is a board-certified neurosurgeon specializing in complex intracranial surgery including brain, pituitary, and skull base tumors, and brain aneurysms.
Dr. Carter is the Chair of the Department of Neurosurgery at Massachusetts General Hospital (MGH) and a visiting professor at Harvard Medical School. One of the nation’s leading clinical neurosurgeons, Dr. Carter co-leads MGH’s brain tumor program, which brings together over 100 faculty and staff focused on brain tumor clinical care, research, and education.
As a prolific researcher, Dr. Carter’s scientific work has included the development of the first reported EGFRvIII directed CAR T-cell therapy, and the first characterizations of exosomes in glioblastoma. He is a principal investigator participating in the NIH-funded Extracellular RNA Communication Consortium. Dr. Carter leads a team of clinician-scientists who have developed the role of “big data” in characterizing outcomes in oncologic and vascular neurosurgery.
Dr. Carter is extensively published, and he lectures internationally on neurosurgery topics. He is an editorial board member for the Journal of Neurosurgery and editorial advisory board member for Neurosurgery.
Prior to joining MGH, Dr. Carter served as Professor and Chair of Neurosurgery at the UC San Diego School of Medicine.
Consistently elected to America’s Top Doctors®, Dr. Carter is a fellow of the American Association of Neurological Surgeons and a member of numerous medical organizations, including the Congress of Neurological Surgeons and the American Academy of Neurological Surgery. He serves on the program committee for the American Stroke Association’s International Stroke Conference and has served on the executive boards of the Joint Cerebrovascular Section and the New England Neurosurgical Society.
The search for effective treatments for Parkinson’s disease is ongoing. Join our mailing list to stay up to date on the latest advances.
Personalizing Stem Cell Therapy for Parkinson’s Disease
In the U.S. alone, as many as one million people have Parkinson’s disease. Kwang-Soo Kim, PhD, is committed to finding a way to lower those numbers.
First-in-Human Therapy With Stem Cell-Derived Dopaminergic Progenitor Cells for Parkinson’s Disease
MGH-McLean team have become the first to implant patient-derived midbrain dopaminergic progenitor cells into a patient with Parkinson’s.
Patient-Derived Dopamine Neurons Show Promise in Parkinson’s Treatment
A study published in the New England Journal of Medicine describes the innovative treatment of a Parkinson’s disease patient.